Paper41323732
Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities.
Wu L and 5 others. Front Cell Dev Biol, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities. Papers, record 41323732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41323732
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References128
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33339441 | Various Aspects of a Gene Editing System-CRISPR-Cas9. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33339441 | PubMed |
| 2 | 36229464 | Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. | Nat Commun | 2022 | https://conductscience.org/library/papers/36229464 | PubMed |
| 3 | 37832401 | Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37832401 | PubMed |
| 4 | 25139413 | PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer. | Oncology | 2014 | https://conductscience.org/library/papers/25139413 | PubMed |
| 5 | 34572980 | Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34572980 | PubMed |
| 6 | 27197252 | Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. | Cancer Res | 2016 | https://conductscience.org/library/papers/27197252 | PubMed |
| 7 | 32778095 | Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. | BMC Cancer | 2020 | https://conductscience.org/library/papers/32778095 | PubMed |
| 8 | 35468964 | HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. | Nat Genet | 2022 | https://conductscience.org/library/papers/35468964 | PubMed |
| 9 | 36919762 | Metabolic shift towards oxidative phosphorylation reduces cell-density-induced cancer-stem-cell-like characteristics in prostate cancer in vitro. | Biol Open | 2023 | https://conductscience.org/library/papers/36919762 | PubMed |
| 10 | 33754187 | Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). | Cancer Chemother Pharmacol | 2021 | https://conductscience.org/library/papers/33754187 | PubMed |
| 11 | 36519314 | Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. | Expert Opin Ther Targets | 2022 | https://conductscience.org/library/papers/36519314 | PubMed |
| 12 | 37922438 | Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/37922438 | PubMed |
| 13 | 40705094 | Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. | Eur J Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/40705094 | PubMed |
| 14 | 33557050 | Treating Prostate Cancer by Antibody-Drug Conjugates. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33557050 | PubMed |
| 15 | 37797680 | Survivin-targeted nanomedicine for increased potency of abiraterone and enzalutamide against prostate cancer. | Eur J Pharm Biopharm | 2023 | https://conductscience.org/library/papers/37797680 | PubMed |
| 16 | 33781305 | Prostate cancer and PARP inhibitors: progress and challenges. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/33781305 | PubMed |
| 17 | 37298192 | Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37298192 | PubMed |
| 18 | 35532818 | The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. | Cell Mol Life Sci | 2022 | https://conductscience.org/library/papers/35532818 | PubMed |
| 19 | 34919143 | Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. | J Exp Med | 2022 | https://conductscience.org/library/papers/34919143 | PubMed |
| 20 | 33643546 | Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. | J Extracell Vesicles | 2021 | https://conductscience.org/library/papers/33643546 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882486 | Homoharringtonine Suppresses Prostate Cancer Progression Through Modulation of the TNF/NF-κB and MAPK Signaling Pathways. | Cells | 2026 | https://conductscience.org/library/papers/42882486 | PubMed |
| 42511541 | Serum CCL2 and CCL7 in Prostate Cancer: Evaluation of Their Diagnostic Utility in Comparison with Benign Prostatic Hyperplasia and Healthy Controls. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511541 | PubMed |
| 42122189 | CRLF1 Drives Prostate Cancer Progression via COMP-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122189 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41323732
GET https://conductscience.org/api/papers/v1/41323732/references?page=2